Supplementary material

Primary endpoint sensitivity analyses – ITT and PP analysis sets

Sensitivity analyses of the primary outcome were performed using the ITT and PP analysis sets. For the analysis using the ITT, missing WOMAC pain subscale scores at week 26 were imputed using last observation carried forward (LOCF). No imputation was used for the analysis using the PP analysis set.

Supplementary Table S1. Change from baseline in WOMAC pain at week 26 – ITT and PP analysis sets.

	HA	iPAAG	Treatment difference	Non-inferiority* (yes/no)
Change from baseline in transformed WOMAC pain subscale (0–100) - ITT	-14.8** (-17.9; -11.7) (n=117)	-18.5 (-21.6; -15.4) (n=115)	3.7 (-0.7; 8.1)	Yes
Change from baseline in transformed WOMAC pain subscale (0–100) - PP	-16.4 (-19.7; -13.1) (n=99)	-18.8 (-22.1; -15.5) (n=99)	2.3 (-2.3; 7.0)	Yes

*If the lower bound of the 95% confidence interval (CI) > -9, the objective of non-inferiority is met. Superiority is declared if the lower bound of the 95% CI >0.
**LOCF applied for missing values. Values are least squares means (95% confidence interval) unless otherwise stated.
HA: hyaluronic acid; iPAAG: injectable polyacrylamide hydrogel; n: number of participants contributing to analysis; WOMAC: Western Ontario and McMaster Universities Osteoarthritis Index; ITT: intention to treat analysis set; PP: per protocol analysis set.